[1]黄凤仙,靳荣辉,高 晖,等.两种不同放疗方案联合热疗治疗骨转移瘤临床研究[J].陕西医学杂志,2021,50(5):550-554.[doi:DOI:10.3969/j.issn.1000-7377.2021.05.009]
　HUANG Fengxian,JIN Ronghui,GAO Hui,et al.Clinical efficacy of two different radiotherapy regimens combined with hyperthermia in treatment of bone metastases[J].,2021,50(5):550-554.[doi:DOI:10.3969/j.issn.1000-7377.2021.05.009]
点击复制

两种不同放疗方案联合热疗治疗骨转移瘤临床研究
分享到：

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
50
期数:
2021年5期
页码:
550-554
栏目:
临床研究
出版日期:
2021-05-05

文章信息/Info

Title:
Clinical efficacy of two different radiotherapy regimens combined with hyperthermia in treatment of bone metastases
作者:
黄凤仙; 靳荣辉; 高 晖; 赵淑红; 刘 屹
(陕西省人民医院,陕西 西安 710068)
Author(s):
HUANG Fengxian; JIN Ronghui; GAO Hui; ZHAO Shuhong; LIU Yi
(Shaanxi Provincial People's Hospital,Xi'an 710068,China)
关键词:
骨转移瘤;  放疗;  热疗;  爆发痛;  放疗方案;  骨相关事件
Keywords:
Bone metastases;  Radiotherapy;  Hyperthermia;  Pain flare;  Radiotherapy schedule;  Skeletal related events
分类号:
R 730.5
DOI:
DOI:10.3969/j.issn.1000-7377.2021.05.009
文献标志码:
A
摘要:
目的:比较两种不同放疗方案联合热疗治疗骨转移瘤的有效性及安全性。方法:选取骨转移瘤患者85例,随机分为单次放疗组(SF组,43例)和多次放疗组(MF组,42例),两组均采用局部放疗同步联合热疗方式进行止痛治疗。结果:放疗结束1个月后SF组和MF组的疼痛总缓解率分别为79.07% 与 88.10%(P>0.05); 全组患者治疗结束1个月后NRS、KPS评分较治疗前明显下降(均P<0.05),而两组间NRS、KPS评分以及△NRS、△KPS比较均差异无统计学意义(均P>0.05); SF组和MF组在放疗第1～14天内爆发痛发生率分别为32.56%与26.19%(P>0.05); 治疗期间两组间1～3级急放射胃肠道损伤、血液学毒性等急性放射性损伤发生率比较均无统计学差异(均P>0.05),全组均未发生4级及以上急性放射损伤; 治疗期间两组间的热疗相关不良事件发生率比较均无统计学差异(均P>0.05); 治疗结束2年内两组间在疼痛再治疗、骨相关事件发生率等方面比较均无统计学差异(均P>0.05)。结论:在骨转移患者的止痛治疗中,8 Gy/1 f的放疗方案联合热疗在疼痛总缓解率、疼痛评分下降、KPS改善等方面不劣于30 Gy/10 f联合热疗,且没有增加爆发痛、放疗相关不良事件、热疗相关不良事件的发生。
Abstract:
Objective:To compare the effectiveness and safety of two different radiotherapy regimens combined with hyperthermia in the treatment of patients with bone metastases.Methods:A total of 85 patients with bone metastases were enrolled.They were randomly divided into the single-fraction radiotherapy group(SF group,43 cases)and multi-fraction radiotherapy group(MF group,42 cases).Both groups were treated with simultaneous local radiotherapy combined with hyperthermia for analgesia.Results:One month after the end of radiotherapy,the overall response rates of the SF group and the MF group were 79.07% and 88.10%,respectively(all P>0.05).The NRS,KPS scores and △NRS,△KPS of the two groups were significantly lower than those before the treatment(all P<0.05),while the difference between the two groups in NRS and KPS scores,and △NRS,△KPS between the two groups was not statistically significant(all P>0.05).The incidence of pain flare during the 1-14 days of radiotherapy in the SF group and the MF group was 32.56% and 26.19%,respectively(P>0.05).During the treatment period,there was no significant difference in the incidence of acute radiation injury such as grade 1 to 3 acute radiation gastrointestinal injury and hematological toxicity between the two groups(all P>0.05),and no acute radiation injury of grade 4 and above occurred; there was no statistical difference in the incidence of hyperthermia-related adverse events between the groups(all P>0.05).There was no statistical difference in the re-treatment of pain and skeletal related events between the two groups within 2 years after treatment(all P>0.05).Conclusion:In the analgesic treatment of patients with symptomatic bone metastases,the 8 Gy/1f radiotherapy schedule combined with hyperthermia is not inferior to 30 Gy/10f combined with hyperthermia in terms of overall response rate、pain score reduction and KPS improvement.Furthermore,there is no increase in the occurrence of pain flare rate,radiotherapy-related adverse events and hyperthermia-related adverse events.

参考文献/References:

[1] Huang JF,Shen J,Li X,et al.Incidence of patients with bone metastases at diagnosis of solid tumors in adults:A large population-based study[J].Ann Transl Med,2020,8(7):482.
[2] Xiong Z,Deng G,Huang X,et al.Bone metastasis pattern in initial metastatic breast cancer:A population-based study[J].Cancer Manag Res,2018,10:287-295.
[3] Klaassen Z,Howard LE,Hoedt A,et al.Factors predicting skeletal-related events in patients with bone metastatic castration-resistant prostate cancer[J].Cancer,2017,123(9):1528-1535.
[4] Yang Y,Ma Y,Sheng J,et al.A multicenter,retrospective epidemiologic survey of the clinical features and management of bone metastatic disease in China[J].Chin J Cancer,2016,35:40.
[5] Coleman RE.Impact of bone-targeted treatments on skeletal morbidity and survival in breast cancer[J].Oncology(Williston Park),2016,30(8):695-702.
[6] Ferrell BR,Temel JS,Temin S,et al.Integration of palliative care into standard oncology care:American society of clinical oncology clinical practice guideline update[J].J Clin Oncol,2017,35(1):96-112.
[7] 肖绍文,吴稚冰,张 珂.肿瘤热疗中国专家共识[J].实用肿瘤杂志,2020,34(1):1-10.
[8] 于 娇,田应选,彭建美,等.调强放疗联合内生场热疗治疗恶性肿瘤骨转移性疼痛的临床研究[J].现代肿瘤医学,2019,34(22):4069-4073.
[9] Chi MS,Yang KL,Chang YC,et al.Comparing the effectiveness of combined external beam radiation and hyperthermia versus external beam radiation alone in treating patients with painful bony metastases:A phase 3 prospective,randomized,controlled trial[J].Int J Radiat Oncol Biol Phys,2018,100(1):78-87.
[10] 姚金娥,管 静,马 蕊.内生场热疗配合放化疗对骨转移癌疗效的临床研究[J].吉林医学,2019,39(5):1066-1067.
[11] Chow E,Hoskin P,Mitera G,et al.Update of the international consensus on palliative radiotherapy endpoints for future clinical trials in bone metastases[J].Int J Radiat Oncol Biol Phys,2012,82(5):1730-1737.
[12] 唐亚荣.循环热灌注化疗联合替吉奥及热疗治疗老年胃癌癌性腹水临床研究[J].陕西医学杂志,2019,48(4):435-437,441.
[13] 童瑞敏.中药保留灌肠联合深部热疗治疗癌性腹痛经验[J].中华针灸电子杂志,2020,25(2):75-76.
[14] 何宁一,洪月光.利水蠲饮方联合腔内热灌注治疗乳腺癌胸腔积液疗效观察[J].陕西中医,2015,36(9):1165-1166.
[15] 金 秀,齐 青,王云晓,等.热疗联合放疗治疗中晚期胃癌的疗效观察[J].肿瘤药学,2020,23(3):320-323.
[16] 赵 凯,王志武,杨俊泉.热疗联合放化疗治疗局部晚期非小细胞肺癌的临床效果[J].中国医药导报,2020,42(11):84-87.
[17] Wang Y,Hong W,Che S,et al.Outcomes for hyperthermia combined with concurrent radiochemotherapy for patients with cervical cancer[J].Int J Radiat Oncol Biol Phys,2020,107(3):499-511.
[18] Saito T,Toya R,Oya N.Pain response rates after conventional radiation therapy for bone metastases in prospective nonrandomized studies:A systematic review[J].Pract Radiat Oncol,2019,9(2):81-88.
[19] Westhoff PG,Verdam M,Oort FJ,et al.Course of quality of life after radiation therapy for painful bone metastases:A detailed analysis from the dutch bone metastasis study[J].Int J Radiat Oncol Biol Phys,2016,95(5):1391-1398.
[20] Goldfinch R,White N.An investigation into the incidence of pain flare in patients undergoing radiotherapy for symptomatic bone metastases[J].Radiography(Lond),2018,24(3):192-195.
[21] Fabregat C,Almendros S,Navarro-Martin A,et al.Pain flare-effect prophylaxis with corticosteroids on bone radiotherapy treatment:A systematic review[J].Pain Pract,2020,20(1):101-109.
[22] Rich SE,Chow R,Raman S,et al.Update of the systematic review of palliative radiation therapy fractionation for bone metastases[J].Radiother Oncol,2018,126(3):547-557.

相似文献/References:

[1]邵渊.上颌窦癌临床特征及治疗[J].陕西医学杂志,2021,50(4):387.[doi:DOI:10.3969/j.issn.1000-7377.2021.04.001]
[2]刘贤国,徐红玉,朱 江.原发性肝癌伴门静脉癌栓产生机制及经导管肝动脉化疗栓塞术联合其他介入方案治疗研究进展[J].陕西医学杂志,2023,52(10):1438.[doi:DOI:10.3969/j.issn.1000-7377.2023.10.036]
　LIU Xianguo,XU Hongyu,ZHU Jiang.Research progress on mechanism of thrombus formation of primary liver cancer with portal vein cancer and application progress of TACE combined with other interventional protocols[J].,2023,52(5):1438.[doi:DOI:10.3969/j.issn.1000-7377.2023.10.036]

备注/Memo

备注/Memo:
基金项目:国家自然科学基金资助项目(81402012); 陕西省自然科学基金资助项目(2019JM-547)
更新日期/Last Update: 2021-05-06